This article is part of our Allergy Treatment resource center, covering all aspects of allergy treatment diagnosis, treatment, and management.
Quick Answer
Prescription allergy treatments are considered when OTC medications do not adequately control symptoms, when asthma is present alongside allergies, or when a clinician determines a patient may benefit from allergen immunotherapy or biologics. Prescription options include stronger intranasal medications, leukotriene receptor antagonists, prescription-only eye medications, short-course systemic corticosteroids, immunotherapy, biologic agents, and epinephrine auto-injectors.
Most people with mild to moderate allergic rhinitis manage well with OTC allergy medications. However, prescription therapies — managed through the broader context of allergy treatment planning — may be appropriate when symptoms remain uncontrolled, when comorbid conditions are present, or when a clinician recommends a different therapeutic approach.
When OTC Treatment May Be Insufficient
Signs that a clinician evaluation may be worthwhile include: symptoms that significantly disrupt sleep, work, or school despite consistent OTC treatment; nasal symptoms year-round rather than seasonally; frequent need for decongestant sprays; associated asthma, chronic sinusitis, or nasal polyps; or interest in a treatment that addresses the underlying immune sensitization rather than only suppressing symptoms. A board-certified allergist can evaluate your triggers and recommend a personalized plan.
Prescription Nasal Medications
Several intranasal corticosteroids are available by prescription only, including ciclesonide, flunisolide, and beclomethasone dipropionate. These may be prescribed when OTC options have not provided sufficient relief or when specific formulations are preferred. A fixed-dose combination product (azelastine + fluticasone) is available by prescription and provides simultaneous antihistamine and corticosteroid activity in a single spray — an option some clinicians consider for patients with moderate-to-severe allergic rhinitis. See the nasal spray treatment guide for a full comparison of nasal spray categories.
Leukotriene Receptor Antagonists
Montelukast (Singulair) and related leukotriene receptor antagonists (LTRAs) are prescription medications that block leukotriene receptors involved in nasal inflammation and airway constriction. They are approved for allergic rhinitis and as add-on therapy for asthma. Their anti-inflammatory effect differs from both antihistamines and corticosteroids, and they are sometimes used in combination with other allergy medications.
Important: The FDA has required a Boxed Warning for montelukast since 2020, noting the risk of serious neuropsychiatric adverse reactions including agitation, anxiety, depression, sleep disturbances, and suicidal thinking. Clinicians are generally advised to reserve montelukast for patients who have not responded to or cannot tolerate first-line alternatives. Discuss this warning with a prescriber before starting.
Prescription Eye Medications
For allergic conjunctivitis not adequately treated by OTC antihistamine eye drops, prescription options include stronger antihistamine/mast-cell stabilizer combinations, corticosteroid eye drops for short-term use in severe cases (with ophthalmologist oversight due to pressure and cataract risks), and in some cases topical calcineurin inhibitors. These require clinician assessment to match the treatment to the severity and nature of the eye condition.
Short-Term Systemic Corticosteroids
Oral corticosteroids such as prednisone may occasionally be prescribed for brief courses to manage severe, acute allergy flares or nasal polyp-related obstruction that has not responded to other treatments. These are not appropriate for routine ongoing allergy management. Risks from prolonged systemic corticosteroid use — including bone density loss, elevated blood glucose, immune suppression, and adrenal suppression — are well established. Use is clinician-supervised with attention to duration and underlying conditions.
Allergen Immunotherapy
Allergen immunotherapy is the only prescription-based treatment that can modify the underlying allergic disease rather than only suppressing symptoms. It involves a multi-year course of allergen exposure under clinical supervision. See our full immunotherapy overview for detailed information on allergy shots, sublingual tablets, and oral immunotherapy for food allergy.
Biologic Medications
Biologic agents for allergic conditions are specialist-prescribed, injectable or infused monoclonal antibodies that target specific immune pathways. Current approvals for allergic or related conditions include:
- Dupilumab: Targets IL-4 and IL-13 signaling; approved for moderate-to-severe atopic dermatitis, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, and moderate-to-severe asthma with eosinophilic phenotype
- Omalizumab: Binds circulating IgE; approved for chronic idiopathic urticaria unresponsive to antihistamines and for moderate-to-severe allergic asthma in appropriate patients
- Mepolizumab, benralizumab, tezepelumab: Target eosinophil pathways; approved for severe eosinophilic asthma with specific indications
Biologics are condition-specific, require specialist oversight, and involve extensive insurance and prior authorization processes. They are not a first-line treatment for typical allergic rhinitis.
Epinephrine Auto-Injectors
For patients with a history of anaphylaxis or at risk for severe allergic reactions, a clinician may prescribe an epinephrine auto-injector (such as EpiPen or Auvi-Q). Epinephrine is the only first-line treatment for anaphylaxis — it is an emergency medication, not a maintenance allergy treatment. Carrying an auto-injector does not reduce the importance of allergen avoidance.
Monitoring and Follow-Up
Prescription allergy management typically involves periodic reassessment of symptom control, treatment tolerability, and whether the chosen approach continues to be appropriate. If asthma is present alongside allergies, spirometry and asthma control assessments are part of regular follow-up. Patients on immunotherapy have scheduled monitoring visits throughout the build-up and maintenance phases. Those on biologics require monitoring per the specific product's prescribing information.
Questions to Discuss With a Clinician
- Have my allergens been identified by testing, or is empirical treatment still being used?
- Is there an underlying condition (asthma, sinusitis, nasal polyps) that is contributing to my symptoms?
- What are the risks and benefits of the specific prescription option being recommended for my situation?
- Would allergen immunotherapy be appropriate for me given my allergen profile and lifestyle?
- Are there interactions with other medicines I take?